Compare Aurobindo Pharma with Unichem Lab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs UNICHEM LAB - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA UNICHEM LAB AUROBINDO PHARMA/
UNICHEM LAB
 
P/E (TTM) x 8.2 94.2 8.7% View Chart
P/BV x 2.0 0.8 260.3% View Chart
Dividend Yield % 0.5 1.4 37.2%  

Financials

 AUROBINDO PHARMA   UNICHEM LAB
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-21
UNICHEM LAB
Mar-21
AUROBINDO PHARMA/
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs1,023360 284.2%   
Low Rs333122 274.1%   
Sales per share (Unadj.) Rs422.8175.4 241.0%  
Earnings per share (Unadj.) Rs92.04.9 1,868.0%  
Cash flow per share (Unadj.) Rs110.016.9 650.6%  
Dividends per share (Unadj.) Rs4.004.00 100.0%  
Avg Dividend yield %0.61.7 35.5%  
Book value per share (Unadj.) Rs374.3362.0 103.4%  
Shares outstanding (eoy) m585.9470.41 832.2%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x1.61.4 116.9%   
Avg P/E ratio x7.448.9 15.1%  
P/CF ratio (eoy) x6.214.2 43.3%  
Price / Book Value ratio x1.80.7 272.5%  
Dividend payout %4.381.2 5.4%   
Avg Mkt Cap Rs m397,39816,954 2,344.0%   
No. of employees `000NANA-   
Total wages/salary Rs m35,3503,070 1,151.6%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m247,74612,351 2,005.8%  
Other income Rs m3,809502 758.8%   
Total revenues Rs m251,55512,853 1,957.1%   
Gross profit Rs m81,480911 8,943.1%  
Depreciation Rs m10,554844 1,251.1%   
Interest Rs m74551 1,455.2%   
Profit before tax Rs m73,990518 14,277.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m20,098172 11,715.4%   
Profit after tax Rs m53,892347 15,545.6%  
Gross profit margin %32.97.4 445.9%  
Effective tax rate %27.233.1 82.1%   
Net profit margin %21.82.8 775.0%  
BALANCE SHEET DATA
Current assets Rs m198,23513,773 1,439.3%   
Current liabilities Rs m106,6525,058 2,108.7%   
Net working cap to sales %37.070.6 52.4%  
Current ratio x1.92.7 68.3%  
Inventory Days Days19155 12.4%  
Debtors Days Days52740 7.0%  
Net fixed assets Rs m135,77817,344 782.8%   
Share capital Rs m586141 416.1%   
"Free" reserves Rs m218,71325,350 862.8%   
Net worth Rs m219,29925,491 860.3%   
Long term debt Rs m1,6840-   
Total assets Rs m334,01331,118 1,073.4%  
Interest coverage x100.311.1 902.0%   
Debt to equity ratio x00-  
Sales to assets ratio x0.70.4 186.9%   
Return on assets %16.41.3 1,279.4%  
Return on equity %24.61.4 1,807.0%  
Return on capital %33.82.2 1,514.0%  
Exports to sales %53.882.8 65.0%   
Imports to sales %16.414.4 113.7%   
Exports (fob) Rs m133,24810,224 1,303.3%   
Imports (cif) Rs m40,6151,780 2,281.6%   
Fx inflow Rs m133,24810,224 1,303.3%   
Fx outflow Rs m44,9461,780 2,524.9%   
Net fx Rs m88,3028,444 1,045.8%   
CASH FLOW
From Operations Rs m33,289331 10,057.5%  
From Investments Rs m5,987-736 -813.9%  
From Financial Activity Rs m-13,648-1,212 1,126.2%  
Net Cashflow Rs m25,831-1,541 -1,676.7%  

Share Holding

Indian Promoters % 48.8 50.1 97.4%  
Foreign collaborators % 3.1 0.0 -  
Indian inst/Mut Fund % 38.4 17.3 221.5%  
FIIs % 23.7 3.9 610.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 48.2 49.9 96.5%  
Shareholders   243,315 23,897 1,018.2%  
Pledged promoter(s) holding % 22.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   VIVIMED LABS  SUVEN PHARMACEUTICALS  NATCO PHARMA  ALKEM LABORATORIES  SMRUTHI ORGANICS  



Today's Market

Sensex Jumps 400 Points to Hit Fresh Record High; Bajaj Finance & ITC Top Gainers(09:30 am)

Asian stock markets are trading on a steady note today as traders weighed risks from China to the global recovery and the prospect of reduced Federal Reserve stimulus.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY22); Net Profit Down 2.0% (Quarterly Result Update)

Aug 16, 2021 | Updated on Aug 16, 2021

For the quarter ended June 2021, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (down 2.0% YoY). Sales on the other hand came in at Rs 57 bn (down 3.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2020-21 Annual Report Analysis (Annual Result Update)

Aug 9, 2021 | Updated on Aug 9, 2021

Here's an analysis of the annual report of AUROBINDO PHARMA for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

Sansera Engineering IPO: Key Points to Consider(Views On News)

Sep 8, 2021

This IPO is a pure OFS and the company is looking to raise Rs 12.8 bn at the upper price band of Rs 744.

5 Stocks that Turned Rs 1 Lakh into Rs 1 Crore(Views On News)

Sep 7, 2021

Patience is one of the biggest virtues you need to have if you want to become a crorepati in the stock market.

The Top Stocks to Sell in this Bull Market(Profit Hunter)

Sep 8, 2021

When I saw the list of so-called 'value stocks' published by a leading brokerage, my worst fears came true.

5 Indian Companies that are Leading the AI Race(Views On News)

Sep 9, 2021

During the pandemic, India reported the highest increase in the use of AI at 45% compared to other major economies. AI has potential to add US$90 bn to the Indian economy by 2025.

Revenge Travel is Here. 9 Stocks Likely to Benefit(Views On News)

Sep 4, 2021

The term 'revenge travel' refers to the desire of going on a vacation after an extended period of lockdown.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2021
Get our special report Multibagger Stocks Guide (2021 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Sep 17, 2021 10:07 AM

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS